^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Breast Cancer
    Drug:Verzenio (abemaciclib) (CDK4 inhibitor, CDK6 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    ASCO.org
    Title:

    Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update

    Published date:
    04/19/2022
    Excerpt:
    Recommendation...a patient with node-positive breast cancer with a high risk of recurrence and a Ki67 score of ≥ 20% as determined by an FDA-approved test may be offered two years of abemaciclib plus endocrine therapy...
    Secondary therapy:
    Hormone Therapy
    DOI:
    10.1200/JCO.22.00069